Drug-drug interactions with tyrosine kinase inhibitors

被引：0
作者：
Janus, N. [1 ]
机构：
[1] LEO Pharma, Global Med Affairs, Voisins Le Bretonneaux, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1926
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1623P
引用
收藏
页码：S1283 / S1283
页数：1
相关论文
共 50 条
[21]   Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib [J].
Haouala, Amina ;
Widmer, Nicolas ;
Duchosal, Michel A. ;
Montemurro, Michael ;
Buclin, Thierry ;
Decosterd, Laurent A. .
BLOOD, 2011, 117 (08) :E75-E87
[22]   Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations [J].
Pajares, Bella ;
Torres, Esperanza ;
Manuel Trigo, Jose ;
Isabel Saez, Maria ;
Ribelles, Nuria ;
Jimenez, Begona ;
Alba, Emilio .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02) :94-101
[23]   Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance [J].
Ferri, Nicola ;
Colombo, Elisa ;
Corsini, Alberto .
HEMATOLOGY REPORTS, 2024, 16 (01) :151-163
[24]   Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists [J].
Gelderblom, H. ;
Koehne, C. H. ;
Launay-Vacher, V. ;
van Leeuwen, R. W. F. .
ANNALS OF ONCOLOGY, 2016, 27 (04) :752-752
[25]   Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors [J].
Garrison, Dominique A. ;
Talebi, Zahra ;
Eisenmann, Eric D. ;
Sparreboom, Alex ;
Baker, Sharyn D. .
PHARMACEUTICS, 2020, 12 (09) :1-18
[26]   DRUG-DRUG INTERACTIONS [J].
FORTH, W .
ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1976, 26 (NA1) :108-114
[27]   DRUG-DRUG INTERACTIONS ASSOCIATED WITH MULTI-CYP INHIBITORS [J].
Hachad, H. ;
Ragueneau-Majlessi, I. ;
Levy, R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 :S29-S30
[28]   Drug-drug interactions [J].
Preskorn, SH .
JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 (05) :223-225
[29]   An update on drug-drug interactions associated with proton pump inhibitors [J].
Ben Ghezala, Ines ;
Luu, Maxime ;
Bardou, Marc .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (05) :337-346
[30]   Tyrosine kinase inhibitors and acid-inhibitory drugs: Strong concomitant dispensing and drug-drug interaction risk [J].
Grude, F. ;
Vigneau-Victorri, C. ;
Lagadec, D. Deniel ;
Michaud, E. ;
Bourgeois, H. ;
Forestier, B. ;
Marhuenda, F. .
ANNALS OF ONCOLOGY, 2018, 29 :658-658
12345